Exhibit 10.57

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

January 28, 2003

 

Dr. David Mitchard

Boehringer Ingelheim International GmBH

Binger Strasse 173

55216 Ingelheim am Rhein

Germany

 

Re:                             Amendment No. 4 to Development and Marketing
Agreement

Dated March 23, 2001 (“Agreement”)

 

Dear David:

 

Words and expressions defined or interpreted in the Agreement shall have the
same meanings and interpretations when used in this letter (the “Amendment”). 
The Agreement is hereby amended to insert the following as Section 2.10:

 

“2.10                   [*]:

 

(a)                                  InterMune [*] BI a [*] for the [*] of any
[*] (as defined in Section 2.10(b)) of [*] as follows:  If [*] of any [*] for
which it [*]
                                                then prior to [*] shall notify
[*] in writing, and shall provide [*] with all [*] reasonably necessary for [*] 
If [*] also intends
                                                such [*] shall also provide [*]
as well as all [*] if any, in its possession and control.  If [*] after any such
notice from [*]
                                                upon which [*] then the parties
shall [*]  If the Parties do not [*] shall have no [*] with respect to such [*]
provided that if
                                                the [*] also would have [*]
shall have no [*] with respect to any [*]  For clarity, [*] as used herein,
specifically [*] including
                                                without limitation a [*]

 

(b)                                 [*] having as its [*] and which may either
be [*]

 

(c)                                  The Parties acknowledge that (1) [*] in
addition to those [*] and (2) except as specifically set forth in [*] in
addition to those [*] the Agreement.

 

(d)                                 [*] the Parties agree that [*] of the
Agreement will [*] of the Agreement.

 

(e)                                  The Parties will [*] prior to [*] in
Article 2.10.

 

1

--------------------------------------------------------------------------------

 

If you agree with the above, please signify your acceptance by signing and
returning one original of this letter.

 

Best regards,

 

InterMune, Inc.

Accepted for and on behalf of
Boehringer Ingelheim International GmbH

 

 

/s/ John J. Wulf

 

 

 

 

John J. Wulf

By:

  /s/ Dr. P. Johann

 

Sr. Vice President of

 

Corporate Development

Name:

   Dr. P. Johann

 

 

 

 

Title:

Authorised Signatories

 

 

 

 

Date

   January 31, 2003

 

 

 

 

 

 

 

 

By:

/s/ C. Jesse

 

 

 

 

Name:

   C. Jesse

 

 

 

 

Title:

     Authorised Signatories

 

 

 

 

Date:

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

2

--------------------------------------------------------------------------------